The Strategic Value Of In-House Delumping For Homogeneous API Production

By Kim Geurts, Scientist PR&D and Manufacturing, Enabling Chemistry

Powder heterogeneity and agglomeration after drying often compromise active pharmaceutical ingredient (API) batch quality, disrupting downstream blending, dosing, and packaging operations. Traditional manual lump breaking or outsourcing particle processing introduces significant supply chain risks, exposure hazards, and operational bottlenecks. Integrating controlled in-house delumping through scalable, modular conical milling breaks down agglomerates without unintentionally degrading primary particle sizes.

This technical process restores material flowability, ensures representative sampling, and mitigates risks related to contamination and product damage during transfers. Operating under validated Good Manufacturing Practice (GMP) standards, precise mechanical de-agglomeration achieves reliable results even with challenging, high-potency (OEB-5) materials—reaching yields up to 98%.

Review the whitepaper to explore detailed qualification data and optimize your solids handling workflow.